← All companies ← TLK Manual TM → ← TLRY Pharmaceuticals TNGX →
TLX, Telix Pharmaceuticals Limited
A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.
The business
What it sells, where the money comes from, the kind of company it is.
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
- What moves the needle
- Gross margin has run about 63% and operating margin about 3.7% through the cycle, a wide spread between price and the cost of what it sells — whether that advantage is durable pricing power or a margin that can erode is the question the record is for. The operating margin has swung widely — from 3.3% to 11% — on a steadier 63% gross margin, so what moves it sits below the gross line, in operating spend and one-off charges more than in the cost of the product itself. The cash cycle has run negative through the cycle (a median of −66 days): the operation is paid before it pays, so working capital releases cash as the business grows rather than tying it up. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has run in the teens (median 18%, above 15% in 2 of 3 years). Owner earnings, the cash-based check, have been thin too. Returns like these are solid but short of clear franchise economics; whether they hold is what the 10-K settles, not the multiple.
Every line is arithmetic on the company's filings, shown in full in the sections below.
The record
Ten years of arithmetic, read across the cycle.
The record, 2023–2025
realized figures from each filing · older years to the left| 2023’23 | 2024’24 | 2025’25 | TTMTTMDec 2025 | |
|---|---|---|---|---|
| Income statement | ||||
| $333M | $517M | $804M | $804M | RevenueRevenue |
| 63% | 65% | 53% | 53% | Gross marginGross mgn |
| $11M | $55M | $30M | $30M | Operating incomeOp. inc. |
| 3.3% | 10.7% | 3.7% | 3.7% | Operating marginOp. mgn |
| $4M | $34M | ($7M) | ($7M) | Net incomeNet inc. |
| Cash flow & returns | ||||
| $14M | $27M | ($17M) | ($17M) | Operating cash flowOp. cash |
| $4M | $5M | $22M | $22M | DepreciationDeprec. |
| $6M | ($11M) | ($32M) | ($32M) | Working capital & otherWC & other |
| $6M | $9M | $26M | $26M | CapexCapex |
| 1.9% | 1.8% | 3.2% | 3.2% | Capex / revenueCapex/rev |
| $10M | $23M | ($43M) | ($43M) | Owner earningsOwner earn. |
| 2.9% | 4.4% | −5.3% | −5.3% | Owner earnings marginOE mgn |
| $8M | $18M | ($43M) | ($43M) | Free cash flowFCF |
| 2.4% | 3.6% | −5.3% | −5.3% | Free cash flow marginFCF mgn |
| 44% | 18% | 3% | 3% | ROICROIC |
| 4% | 10% | -2% | -2% | Return on equityROE |
| 4% | 10% | −2% | −2% | Retained to equityRetained/eq |
| Balance sheet | ||||
| $84M | $440M | $142M | $142M | Cash & investmentsCash+inv |
| $44M | $87M | $129M | $129M | ReceivablesReceiv. |
| $13M | $24M | $37M | $37M | InventoryInvent. |
| $54M | $87M | $150M | $150M | Accounts payablePayables |
| $2M | $24M | $16M | $16M | Operating working capitalOper. WC |
| $159M | $570M | $330M | $330M | Current assetsCur. assets |
| $111M | $205M | $232M | $232M | Current liabilitiesCur. liab. |
| 1.4× | 2.8× | 1.4× | 1.4× | Current ratioCurr. ratio |
| — | $67M | $199M | $199M | GoodwillGoodwill |
| $277M | $940M | $1.2B | $1.2B | Total assetsAssets |
| $7M | $354M | $405M | $405M | Total debtDebt |
| ($78M) | ($86M) | $263M | $263M | Net debt / (cash)Net debt |
| 1.2× | 2.3× | 0.7× | 0.7× | Interest coverageInt. cov. |
| $103M | $353M | $415M | $415M | Shareholders’ equityEquity |
| Per share | ||||
| 319M | 331M | 338M | 338M | Shares out (diluted)Shares |
| $1.04 | $1.56 | $2.38 | $2.38 | Revenue / shareRev/sh |
| $0.01 | $0.10 | $-0.02 | $-0.02 | EPS (diluted)EPS |
| $0.03 | $0.07 | $-0.13 | $-0.13 | Owner earnings / shareOE/sh |
| $0.02 | $0.06 | $-0.13 | $-0.13 | Free cash flow / shareFCF/sh |
| $0.02 | $0.03 | $0.08 | $0.08 | Cap. spending / shareCapex/sh |
| $0.32 | $1.07 | $1.23 | $1.23 | Book value / shareBVPS |
The record, charted
FY2023–2025Each measure over its full record; the current point and the worst year marked.
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business reported a $7M loss but ($43M) of owner earnings: $36M less than the profit line, taken out by capital spending and the timing of cash.
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Reported net income | ($7M) | $34M | $4M |
| Depreciation & amortizationnon-cash charge added back | +$22M | +$5M | +$4M |
| Working capital & othertiming of cash in and out, other non-cash items | −$32M | −$11M | +$6M |
| Cash from operations | ($17M) | $27M | $14M |
| Maintenance capital expenditurethe spending needed just to hold position and volume | −$26M | −$5M | −$4M |
| Owner earnings | ($43M) | $23M | $10M |
| Growth capital expenditurediscretionary; spent to get bigger, not to stand still | — | −$4M | −$2M |
| Free cash flow | ($43M) | $18M | $8M |
| Owner-earnings marginowner earnings ÷ revenue | -5% | 4% | 3% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
“We have identified a material weakness in our internal control over financial reporting.”
The figures below are only as sound as the controls that produced them. read the note →
Will it survive?
- Does not cover its interestOperating income $30M ÷ interest expense $41M
What this means
A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.
- How heavy is the debt, net of cash? $263M · 8.8× operating profitHeavy net debtCash $142M − debt $405M
What this means
Netting $142M of cash and short-term investments against $405M of debt leaves $263M owed, about 8.8× a year's operating profit (13.6× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Negative, funded by othersDSO 59 + DIO 36 − DPO 145 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. A negative cycle is a quiet moat: suppliers and customers fund the operation (Buffett's “float”), the company grows on other people's money.
Is it a good business?
- High through the cycle3-yr median, range 3%–44%; 3% latest = NOPAT $24M ÷ invested capital $679MIndustry peers: median 6%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 3 years (it ran 3% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- Thin through the cycle3-yr median margin, range -5%–4%; latest ($43M) = operating cash ($17M) − maintenance capex $26MIndustry peers: median 17%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -5% of revenue this year, a 3% median across 3 years.
- Are earnings backed by cash? ($17M)Loss, and burning cashNet income ($7M) · cash from operations ($17M)
In the filing’s words The filing discloses a material weakness in its financial controls — the reported numbers here, and the record built on them, are only as reliable as the controls that produced them.
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.
How is the cash used?
- Not enough data
What this means
The filing data didn't include the inputs for this check.
- Investing or harvesting? 1.19×MaintainingCapex $26M ÷ depreciation $22M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 0 of 3 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $804M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity MissCurrent ratio ≥ 2× · 1.43×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt MissDebt ≤ working capital · $405M vs $99M WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $0.03/share (latest year $-0.02), the averaged base the calculator's gate runs on, and book value is $1.23/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Does AI threaten the moat?
Low contestabilityThe moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.
Its FY2025 10-K names artificial intelligence as a competitive threat, in language that was not in the prior year's filing.
“Our failure to use AI technologies in a way that maintains trust, quality and control in our business activities and to capitalize on opportunities presented by AI may also place us at a competitive disadvantage.”
AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of fiscal year-end, Dec 31, 2025Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$142M
- Receivables$129M
- Inventory$37M
- Other current assets$22M
- Debt due within a year$13M
- Accounts payable$150M
- Other current liabilities$68M
From the company's latest filing.
Acquisitions & goodwill
from the balance sheet & the 3-year cash-flow recordGoodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.
None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.
Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and write-downs summed across the 3-year record, from the company's own filings.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| ANIPANI Pharmaceuticals Inc. | $883M | 62% | 8.8% | 4% | 17% |
| HRMYHarmony Biosciences Holdings Inc. | $868M | 79% | 26.7% | 38% | 32% |
| ARWRArrowhead Pharmaceuticals | $829M | — | -106.8% | -51% | -77% |
| TLXTelix Pharmaceuticals Limited | $804M | 63% | 3.7% | 18% | 3% |
| COLLCollegium Pharmaceutical Inc. | $781M | 56% | 6.8% | 44% | 31% |
| CORTCorcept Therapeutics Incorporated | $761M | 98% | 30.6% | 25% | 34% |
| EBSEmergent BioSolutions Inc. | $743M | 58% | 12.5% | 6% | 8% |
| PCRXPacira BioSciences | $726M | 73% | 3.7% | 2% | 16% |
| Group median | — | 63% | 7.8% | 12% | 16% |
The price
What a price has to assume.
What the price implies
reverse-DCFEnter the US price, in dollars: the NYSE/Nasdaq quote you hold. Per the filing's own cover, “American depositary shares , each representing one ordinary”; Telix Pharmaceuticals Limited reports in USD, so every figure in this tool is stated per ADS so your dollar quote reconciles exactly. The record tables elsewhere on this page remain as filed.
Telix Pharmaceuticals Limited is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.
Enter a price to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.
Manual order: ← TLK its page in the Manual TM →
Industry order: ← TLRY the Pharmaceuticals chapter TNGX →